Vericel Corporation (NASDAQ: VCEL), a leading developer of patient-specific cellular therapies, has signed a long-term supply agreement with our member Matricel GmbH for the ACI-Maix collagen membrane. The CEO of Vericel Corporation, Nick Colangelo, stated in a press release published on October 26, 2015: "Matricel's proprietary collagen scaffold technology and previous experience as a reliable supplier of the ACI-Maix membrane for MACI make Matricel a valuable partner for us as we pursue registration of MACI in the United States. We look forward to a long and productive relationship with Matricel." (Source www.marketwired.com)